BR9811474A - Derivados de 3-oxadiazolil-1, 6-naftiridin-2 (1h)-ona-5-substituìdo - Google Patents

Derivados de 3-oxadiazolil-1, 6-naftiridin-2 (1h)-ona-5-substituìdo

Info

Publication number
BR9811474A
BR9811474A BR9811474-3A BR9811474A BR9811474A BR 9811474 A BR9811474 A BR 9811474A BR 9811474 A BR9811474 A BR 9811474A BR 9811474 A BR9811474 A BR 9811474A
Authority
BR
Brazil
Prior art keywords
oxadiazolyl
optionally substituted
lower alkyl
substituted derivatives
substituted aryl
Prior art date
Application number
BR9811474-3A
Other languages
English (en)
Other versions
BR9811474B1 (pt
Inventor
Kazunori Ohno
Osamu Odai
Kaoru Masumoto
Kiyoshi Furukawa
Makoto Oka
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Publication of BR9811474A publication Critical patent/BR9811474A/pt
Publication of BR9811474B1 publication Critical patent/BR9811474B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DE 3-OXADIAZOLIL-1, 6-NAFTIRIDIN-2 (1H)-ONA-5-SUBSTITUìDO" Novos derivados de 3-oxadiazolil-1, 6-naftiridin-2 (1H)-ona-5-substituído representados pela fórmula geral (I), onde Het representa oxadiazolila, R^ 1^ representa H, alquila inferior, cicloalquila inferior, alquenila inferior, alcóxi inferior, arila opcionalmente substituída, heteroarila opcionalmente substituída, etc.; e R^ 2^ representa H, alquila inferior, ciclo alquila inferior, arila opcionalmente substituída, etc. Devido ao fato das altas afinidades de seletividade com os receptores de benzodiazepina, estes compostos são úteis como agonistas de receptor de benzodiazepina, especificamente agonistas inversos dos mesmos, por exemplo, ativadores cerebrais e remédios para distúrbios da memória, associados a demência senil, doença de Alzheimer, etc.
BRPI9811474-3A 1997-07-15 1998-07-14 derivados de 3-oxadiazolil-1, 6-naftiridin-2 (1h)-ona-5-substituìdo. BR9811474B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20717997 1997-07-15
PCT/JP1998/003134 WO1999003857A1 (fr) 1997-07-15 1998-07-14 Derives de 5-substitue-3-oxadiazolyl-1,6-naphtyridin-2(1h)-one

Publications (2)

Publication Number Publication Date
BR9811474A true BR9811474A (pt) 2000-08-15
BR9811474B1 BR9811474B1 (pt) 2009-05-05

Family

ID=16535559

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9811474-3A BR9811474B1 (pt) 1997-07-15 1998-07-14 derivados de 3-oxadiazolil-1, 6-naftiridin-2 (1h)-ona-5-substituìdo.

Country Status (29)

Country Link
US (2) US6172079B1 (pt)
EP (1) EP1010699B1 (pt)
JP (1) JP3390453B2 (pt)
KR (1) KR100508392B1 (pt)
CN (1) CN1134437C (pt)
AR (1) AR013222A1 (pt)
AT (1) ATE297923T1 (pt)
AU (1) AU735960B2 (pt)
BR (1) BR9811474B1 (pt)
CA (1) CA2296427C (pt)
DE (1) DE69830595T2 (pt)
DK (1) DK1010699T3 (pt)
EE (1) EE04372B1 (pt)
ES (1) ES2244065T3 (pt)
HK (1) HK1028895A1 (pt)
HU (1) HUP0004671A3 (pt)
ID (1) ID24047A (pt)
IL (2) IL133512A0 (pt)
NO (1) NO314999B1 (pt)
NZ (1) NZ501814A (pt)
PL (1) PL191200B1 (pt)
PT (1) PT1010699E (pt)
RU (1) RU2188199C2 (pt)
SI (1) SI1010699T1 (pt)
SK (1) SK285913B6 (pt)
TR (1) TR200000103T2 (pt)
TW (1) TW486479B (pt)
WO (1) WO1999003857A1 (pt)
ZA (1) ZA985870B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI298068B (en) * 2000-06-21 2008-06-21 Dainippon Sumitomo Pharma Co Pharmaceutical composition for schizophrenia
TW200533371A (en) * 2004-04-15 2005-10-16 Dainippon Pharmaceutical Co Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
CN101541311B (zh) 2006-10-25 2013-01-23 大日本住友制药株式会社 不易结块的颗粒制剂
MX2010009207A (es) * 2008-02-22 2011-03-03 Irm Llc Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
WO2010002451A1 (en) * 2008-07-01 2010-01-07 Concert Pharmaceuticals, Inc. Naphthyridin derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415580A (en) 1982-08-02 1983-11-15 Sterling Drug Inc. Certain 2-(1H)-pyridinones cardiotonic compositions containing same and method of using same
US4650806A (en) * 1985-01-14 1987-03-17 Sterling Drug Inc. Cardiotonic 5-(heterylcarbonyl)-pyridones
US4567186A (en) * 1985-01-14 1986-01-28 Sterling Drug Inc. 5-Heteryl-1,6-naphthyridin-2(1H)-ones, cardiotonic use thereof and intermediates therefor
DK151890D0 (da) * 1990-06-22 1990-06-22 Ferrosan As Heterocykliske forbindelser deres fremstilling og brug
AU1625192A (en) * 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
AU664912B2 (en) * 1992-09-02 1995-12-07 Dainippon Pharmaceutical Co. Ltd. Novel 3-oxadiazolyl-1,6-naphthyridine derivatives
JP2002241379A (ja) * 1997-03-21 2002-08-28 Dainippon Pharmaceut Co Ltd ３−オキサジアゾリルキノキサリン誘導体

Also Published As

Publication number Publication date
US6277993B1 (en) 2001-08-21
AR013222A1 (es) 2000-12-13
TR200000103T2 (tr) 2000-06-21
PL338085A1 (en) 2000-09-25
EP1010699B1 (en) 2005-06-15
CN1264380A (zh) 2000-08-23
IL133512A0 (en) 2001-04-30
ES2244065T3 (es) 2005-12-01
CA2296427A1 (en) 1999-01-28
DK1010699T3 (da) 2005-10-10
ZA985870B (en) 1999-01-27
PT1010699E (pt) 2005-08-31
EE200000029A (et) 2000-10-16
DE69830595D1 (de) 2005-07-21
HK1028895A1 (en) 2001-03-09
EP1010699A4 (en) 2001-09-12
AU735960B2 (en) 2001-07-19
RU2188199C2 (ru) 2002-08-27
BR9811474B1 (pt) 2009-05-05
SK285913B6 (sk) 2007-11-02
HUP0004671A3 (en) 2001-12-28
JP3390453B2 (ja) 2003-03-24
ID24047A (id) 2000-07-06
SK532000A3 (en) 2000-09-12
AU8129498A (en) 1999-02-10
CA2296427C (en) 2006-11-14
US6172079B1 (en) 2001-01-09
NO20000183L (no) 2000-03-07
HUP0004671A2 (hu) 2001-05-28
WO1999003857A1 (fr) 1999-01-28
KR100508392B1 (ko) 2005-08-17
NO20000183D0 (no) 2000-01-14
ATE297923T1 (de) 2005-07-15
CN1134437C (zh) 2004-01-14
PL191200B1 (pl) 2006-03-31
EE04372B1 (et) 2004-10-15
NO314999B1 (no) 2003-06-23
KR20010021824A (ko) 2001-03-15
TW486479B (en) 2002-05-11
EP1010699A1 (en) 2000-06-21
SI1010699T1 (en) 2005-10-31
IL133512A (en) 2007-06-17
DE69830595T2 (de) 2006-05-11
NZ501814A (en) 2002-02-01

Similar Documents

Publication Publication Date Title
CY1106486T1 (el) Μεθοδος παρασκευης 2-(κινοξαλιν-5-υλσουλφονυλαμινο) βενζαμιδικων ενωσεων
ATE264856T1 (de) Heterocyclisch substituierte benzolderivate und herbizide
DE69413542T2 (de) Perhydroisoindolderivate als substanz p antagonisten
NO20030471L (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
NO20025186L (no) Fremgangsmåte for syntese av en ecteinascidinforbindelse
MY135686A (en) Indole derivatives useful as histamine h3 antagonists
SE8406585D0 (sv) Benzoic acid derivatives
NO20014957D0 (no) Fremgangsmåte for fremstilling av aminplatinakomplekser
ES2031865T3 (es) Un procedimiento para preparar derivados de imidas.
DE60007347D1 (de) Isoxazolcarboxamid-derivate als antagonisten des alpha1-adrenergischen rezeptors
NO900934L (no) Fremgangsmaate for fremstilling av nye derivater av 4-substituerte piperaziner.
FI963786A0 (fi) Uusia 1,4-disubstituoituja piperidiinijohdannaisia, jotka ovat käyttökelpoisia glutamaattireseptoriin vaikuttavina lääkeaineina
DE69812895D1 (de) Synthese der terfenadin und deren derivate
BR9811474A (pt) Derivados de 3-oxadiazolil-1, 6-naftiridin-2 (1h)-ona-5-substituìdo
FR2654102B1 (fr) Procede de synthese de derives polyazotes cycliques.
WO1996005182A3 (de) Saccharinderivate
NO990890D0 (no) Prosess for produksjon av kontrastmidler
DE69523595D1 (de) Aryl und heteroaryl alkoxynaphtalen derivate
EE200000024A (et) Meetod alküüloksüfuranooni amiinderivaatide valmistamiseks, sel meetodil saadud ühendid ja nende kasutamine
FI973671A (fi) Heterosyklisen substituentin sisältäviä piperatsinonijohdoksia takykiniinireseptoriantagonisteina
DE69906243T2 (de) 2-Indanmethanolderivate und ihre Verwendung als Riechstoffe
NO20014077L (no) Fremgangsmåte for krystallisering av N-(4-trifluormetylfenyl)- 5-metyl-isoksazol-4-karboksamid
NO20002154D0 (no) Nye heterocykliske substituerte alfa-hydroksykarboksylsyre- derivater
NO993013D0 (no) Nye heterosykliske substituerte pyrrolidinamidderivater
AU6520498A (en) Process for producing piperidinecarboxylic acid amides

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/06/2009, OBSERVADAS AS CONDICOES LEGAIS.

B24C Patent annual fee: request for for restoration

Free format text: REFERENTE A 12A E 13A ANUIDADE(S).

B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 12A E 13A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2607 DE 22-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.